Brivaracetam

Drug Profile

Brivaracetam

Alternative Names: BRIVIACT; BRIVLERA; RIKELTA; UCB-34714

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Myoclonic epilepsies; Postherpetic neuralgia

Most Recent Events

  • 18 Sep 2017 Launched for Epilepsy (In adolescents, Monotherapy, In adults) in USA (IV,Injection; PO,Tablet; PO,Liquid)
  • 15 Sep 2017 Registered for Epilepsy (In adolescents, Monotherapy, In adults) in USA (IV,Injection; PO,Tablet; PO,Liquid)
  • 01 Sep 2017 UCB completes a phase III trial for Epilepsy (Adjunctive therapy, In children, In adolescents, In adults, In the elderly) in the USA, Australia, Brazil, Canada, India and Mexico (PO) (NCT00150800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top